印度医护人员对羟氯喹预防冠状病毒2型感染的知识和依从性

IF 0.8 Q4 PHARMACOLOGY & PHARMACY
Journal of Research in Pharmacy Practice Pub Date : 2022-08-18 eCollection Date: 2022-01-01 DOI:10.4103/jrpp.jrpp_50_21
Rudrashish Haldar, Prabhaker Mishra, Mohan Gurjar, Om Prakash Sanjeev, Vijai Datta Upadhyaya, Ankur Bhatnagar, Dharmendra Bhadauria, Vikas Agarwal
{"title":"印度医护人员对羟氯喹预防冠状病毒2型感染的知识和依从性","authors":"Rudrashish Haldar,&nbsp;Prabhaker Mishra,&nbsp;Mohan Gurjar,&nbsp;Om Prakash Sanjeev,&nbsp;Vijai Datta Upadhyaya,&nbsp;Ankur Bhatnagar,&nbsp;Dharmendra Bhadauria,&nbsp;Vikas Agarwal","doi":"10.4103/jrpp.jrpp_50_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>In the initial days of the coronavirus disease 2019 (COVID-19) pandemic, the Indian Council of Medical Research (ICMR) recommended the use of hydroxychloroquine (HCQ) as chemoprophylaxis for health-care workers (HCWs) involved in the care of COVID-19 patients. The present survey aimed to assess the knowledge and compliance of HCQ prophylaxis as per the ICMR recommendations among Indian HCWs during the first wave of the pandemic.</p><p><strong>Methods: </strong>A validated 19-item questionnaire-based survey was distributed to HCWs in our apex tertiary care institute who had completed their duties in the COVID-19 wards to assess the knowledge, attitude, and compliance of all sections of HCWs regarding the ICMR-recommended HCQ prophylaxis. Participation in the survey was voluntary, and anonymity was maintained. Data obtained from the responses were collated and analyzed.</p><p><strong>Findings: </strong>Two hundred and fourteen out of 250 HCWs completed the survey (85.6% response rate). Among 214 participants, 87.9% were below the age of 40 years. 83.2% were aware of the use of HCQ for possible prevention of COVID-19 infection, while only 24.6% took HCQ for 7 weeks as was recommended during that period. The main reasons given by 37.3% of the HCWs for not taking HCQ were their knowledge and research on HCQ, where side effects were prominent. Side effects were reported by 35% of the respondents, of which the most notable was nausea/vomiting (14%) followed by gastritis (12%).</p><p><strong>Conclusion: </strong>The poor compliance with HCQ prophylaxis by HCWs was influenced by their knowledge and research, lack of strong scientific evidence, and drug-associated adverse effects.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 1","pages":"33-39"},"PeriodicalIF":0.8000,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/f7/JRPP-11-33.PMC9585800.pdf","citationCount":"0","resultStr":"{\"title\":\"Knowledge and Compliance of Hydroxychloroquine Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Indian Health-Care Workers.\",\"authors\":\"Rudrashish Haldar,&nbsp;Prabhaker Mishra,&nbsp;Mohan Gurjar,&nbsp;Om Prakash Sanjeev,&nbsp;Vijai Datta Upadhyaya,&nbsp;Ankur Bhatnagar,&nbsp;Dharmendra Bhadauria,&nbsp;Vikas Agarwal\",\"doi\":\"10.4103/jrpp.jrpp_50_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>In the initial days of the coronavirus disease 2019 (COVID-19) pandemic, the Indian Council of Medical Research (ICMR) recommended the use of hydroxychloroquine (HCQ) as chemoprophylaxis for health-care workers (HCWs) involved in the care of COVID-19 patients. The present survey aimed to assess the knowledge and compliance of HCQ prophylaxis as per the ICMR recommendations among Indian HCWs during the first wave of the pandemic.</p><p><strong>Methods: </strong>A validated 19-item questionnaire-based survey was distributed to HCWs in our apex tertiary care institute who had completed their duties in the COVID-19 wards to assess the knowledge, attitude, and compliance of all sections of HCWs regarding the ICMR-recommended HCQ prophylaxis. Participation in the survey was voluntary, and anonymity was maintained. Data obtained from the responses were collated and analyzed.</p><p><strong>Findings: </strong>Two hundred and fourteen out of 250 HCWs completed the survey (85.6% response rate). Among 214 participants, 87.9% were below the age of 40 years. 83.2% were aware of the use of HCQ for possible prevention of COVID-19 infection, while only 24.6% took HCQ for 7 weeks as was recommended during that period. The main reasons given by 37.3% of the HCWs for not taking HCQ were their knowledge and research on HCQ, where side effects were prominent. Side effects were reported by 35% of the respondents, of which the most notable was nausea/vomiting (14%) followed by gastritis (12%).</p><p><strong>Conclusion: </strong>The poor compliance with HCQ prophylaxis by HCWs was influenced by their knowledge and research, lack of strong scientific evidence, and drug-associated adverse effects.</p>\",\"PeriodicalId\":17158,\"journal\":{\"name\":\"Journal of Research in Pharmacy Practice\",\"volume\":\"11 1\",\"pages\":\"33-39\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2022-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/f7/JRPP-11-33.PMC9585800.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Research in Pharmacy Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jrpp.jrpp_50_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_50_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:在2019冠状病毒病(COVID-19)大流行的最初几天,印度医学研究委员会(ICMR)建议参与护理COVID-19患者的卫生保健工作者(HCWs)使用羟氯喹(HCQ)作为化学预防药物。本调查旨在评估印度卫生保健工作者在大流行第一波期间根据ICMR建议对HCQ预防的了解和遵守情况。方法:对我院三级医疗机构完成新冠肺炎病区职责的医护人员进行问卷调查,评估各科室医护人员对icmr推荐的HCQ预防的知识、态度和依从性。参与调查是自愿的,并保持匿名。从回复中获得的数据被整理和分析。结果:250名医护人员中有214名完成了调查,回应率为85.6%。214名参与者中,87.9%的人年龄在40岁以下。83.2%的人知道使用HCQ可以预防COVID-19感染,而只有24.6%的人在此期间按照建议服用了7周HCQ。37.3%的医护人员不服用盐酸环己烷醇的主要原因是对盐酸环己烷醇的了解和研究,其中副作用突出。35%的应答者报告了副作用,其中最显著的是恶心/呕吐(14%),其次是胃炎(12%)。结论:卫生保健工作者对HCQ预防依从性较差,主要受其自身知识和研究水平、缺乏强有力的科学依据和药物相关不良反应的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Knowledge and Compliance of Hydroxychloroquine Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Indian Health-Care Workers.

Knowledge and Compliance of Hydroxychloroquine Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Indian Health-Care Workers.

Knowledge and Compliance of Hydroxychloroquine Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Indian Health-Care Workers.

Objective: In the initial days of the coronavirus disease 2019 (COVID-19) pandemic, the Indian Council of Medical Research (ICMR) recommended the use of hydroxychloroquine (HCQ) as chemoprophylaxis for health-care workers (HCWs) involved in the care of COVID-19 patients. The present survey aimed to assess the knowledge and compliance of HCQ prophylaxis as per the ICMR recommendations among Indian HCWs during the first wave of the pandemic.

Methods: A validated 19-item questionnaire-based survey was distributed to HCWs in our apex tertiary care institute who had completed their duties in the COVID-19 wards to assess the knowledge, attitude, and compliance of all sections of HCWs regarding the ICMR-recommended HCQ prophylaxis. Participation in the survey was voluntary, and anonymity was maintained. Data obtained from the responses were collated and analyzed.

Findings: Two hundred and fourteen out of 250 HCWs completed the survey (85.6% response rate). Among 214 participants, 87.9% were below the age of 40 years. 83.2% were aware of the use of HCQ for possible prevention of COVID-19 infection, while only 24.6% took HCQ for 7 weeks as was recommended during that period. The main reasons given by 37.3% of the HCWs for not taking HCQ were their knowledge and research on HCQ, where side effects were prominent. Side effects were reported by 35% of the respondents, of which the most notable was nausea/vomiting (14%) followed by gastritis (12%).

Conclusion: The poor compliance with HCQ prophylaxis by HCWs was influenced by their knowledge and research, lack of strong scientific evidence, and drug-associated adverse effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Research in Pharmacy Practice
Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
8
审稿时长
21 weeks
期刊介绍: The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信